

There is another way

Utilising ADCs to improve outcomes in patients with triple-negative and HR+/HER2-negative mBC

Wednesday, 14 May 2025 | 18:15–19:15 CEST

Room 5, ICM – International Congress Center Messe München,
Munich, Germany

AGENDA

18:15–18:20

Welcome and introduction



Dr Hope S. Rugo (US)

Director, Women's Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics
Research, City of Hope Medical Centre, Duarte CA, US

18:20–18:35

**ADCs as a treatment option in
previously treated triple-negative
and HR+/HER2-negative mBC**



Dr Hope S. Rugo (US)

Director, Women's Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics
Research, City of Hope Medical Centre, Duarte CA, US

18:35–18:55

**Optimising treatment outcomes with
ADCs in previously treated mTNBC
and HR+/HER2-negative mBC**



Prof. Frederik Marmé (Germany)

Gynaecologic Oncologist, Medical Faculty Mannheim
Heidelberg University, Mannheim, Germany

18:55–19:10

**Exploring ADCs as treatment options
in earlier lines of mBC**



Prof. Rebecca Dent (Singapore)

Senior Consultant, National Cancer Centre
Singapore, Singapore

19:10–19:15

Q&A

All speakers – facilitated by the Chair
Dr Hope S. Rugo (US)



Oncology

ADCs, antibody-drug conjugates; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mBC, metastatic breast cancer; mTNBC, metastatic triple-negative breast cancer.

This symposium is sponsored and organised by Gilead and intended for healthcare professionals only.

The purpose of this symposium is scientific exchange. The audience is encouraged to actively participate in the discussion throughout the symposium after each presentation via the voting system and live during the Q&A.

GILEAD and the GILEAD logo are trade marks of Gilead Sciences, Inc. © 2025 Gilead Sciences, Inc. All rights reserved.

April 2025 | GFM-UNB-0058